Cargando…
Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
BACKGROUND: The current maintenance dose (10,000 AUeq/monthly) of a subcutaneous allergoid for house dust mite (HDM) immunotherapy has previously shown significant clinical efficacy in patients with HDM induced allergic rhinitis or rhinoconjunctivitis. In order to comply with the 2009 EMA guidelines...
Autores principales: | Rieker-Schwienbacher, Juliane, Nell, Marja J, Diamant, Zuzana, van Ree, Ronald, Distler, Andreas, Boot, Johan D, Kleine-Tebbe, Jörg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658910/ https://www.ncbi.nlm.nih.gov/pubmed/23657148 http://dx.doi.org/10.1186/2045-7022-3-16 |
Ejemplares similares
-
Cost-effectiveness of SQ(®) HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany
por: Green, William, et al.
Publicado: (2017) -
Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases
por: Yang, Yaqi, et al.
Publicado: (2021) -
Shrimp sensitization in house dust mite allergic
patients
por: Ukleja-Sokołowska, Natalia, et al.
Publicado: (2020) -
Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children
por: Rattanamanee, Tipyapa, et al.
Publicado: (2022) -
Precision Medicine in House Dust Mite-Driven Allergic Asthma
por: Eguiluz-Gracia, Ibon, et al.
Publicado: (2020)